| [Immunohistochemical study of epidermal growth factor receptor and c-erbB.2 oncogene product in bile duct carcinoma: preliminary report]. | None |
| Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. | None |
| [The expression of proto-oncogene c-erbB(2) and its role in the initiation of primordial follicle growth in rat ovary]. | None |
| Contributory effects of de novo transcription and premature transcript termination in the regulation of human epidermal growth factor receptor proto-oncogene RNA synthesis. | None |
| Differences underlying EGFR and HER2 oncogene addiction. | None |
| Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. | None |
| Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. | None |
| EGFRvIVa and EGFRvIVb mutants that lack internal segments distal to the intracellular tyrosine kinase domain confer an oncogenic potential | None |
| Pharmacologic inactivation of kinase suppressor of Ras1 sensitizes epidermal growth factor receptor and oncogenic Ras-dependent tumors to ionizing radiation treatment. | None |
| Inhibition of epidermal growth factor receptor biosynthesis caused by the src oncogene product, pp60v-src. | None |
| Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. | None |
| Germ-line mutations in EGFR are rare but may contribute to oncogenesis. | None |
| microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. | None |
| Analysis of the role of the extracellular domain of the v-erbB oncogene in cellular transformation. | None |
| The identification of an in-frame splice variant of EGFR expands the mechanisms by which EGFR contributes to oncogenesis and represents the first link between two areas of cancer cell biology: EGFR signaling and the unfolded protein response. | None |
| Two oncogenic mutants of EGFR are fully active independently of EGF and highly resistant to the therapeutic and endogenous inhibitors cetuximab, lapatinib and MIG6. | None |
| Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. | None |
| Inhibition of survival signals and concomitant release of apoptotic potential jointly contribute to the tumor cell death following the inhibition of addicted oncogene in EGFR addicted cancers. | None |
| Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers. | None |
| [Expression of epidermal growth factor receptor and the oncogene c-erbB2 on pulmonary fibrosis induced by bleomycin in rats]. | None |